For Takeda’s alogliptin, the waiting is the hardest part…….

With apologies to Tom Petty, the world will have to wait a few more months to learn alogliptin’s fate.

Just a few weeks ago, we were discussing the very active late January scheduled for the FDA with three new agents PDFUA dates scheduled, alogliptin, dapagliflozin and exenatide QW.

Takeda announced last week the the FDA has re-scheduled the action date for April 25.  Three months will seem like a blink of an eye for Takeda, who received a complete response letter in June 2009.

Nevertheless, 2012 is stacking up as a great year for industry watching.   We are about two months away from the news on dapa and exenatide QW. Tick Tock!

Post a comment or leave a trackback: Trackback URL.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: